A thorough stability assessment of your biologics candidates during early development is crucial to identify and prevent potential downstream issues like aggregation or loss of function from unfolding. High-quality information on your candidates’ biophysical properties facilitates the decision-making process for candidate selection.
Dynamic Light Scattering (DLS) is a powerful method that provides information about the purity and aggregation state of your biologics preps, and adds deeper insight into the stability of your candidates.
The additional stability parameters granted by DLS are easily obtained alongside other stability profiling methods, without additional time or material requirements. Adding DLS information to your stability assessments reveals liabilities missed by other technologies and narrows down your final candidate earlier in your development workflow.
Read this eBook to learn how DLS works, and how it helps you improve the selection process for your candidates.
Ready to tackle your challenging stability characterizations?
Discover toolsSee more related content
42:49Quality control during membrane protein purification for cryo-EM
In this webinar Dr. Melanie McDowell, Research Group Leader at the MPI of Biophysics outlines bottlenecks associated with membrane protein purification for cryo EM and strategies to overcome them
Practical Guide: Quality Control Strategies for Membrane Proteins
When working with membrane proteins, whether you’re troubleshooting aggregation, testing new solubilization strategies, or deciding when to switch detergents read this guide for practical solutions.
Powering Precision: How Automated Analytical Devices are Driving Smarter Biomanufacturing
Learn about Prometheus Panta C: A next-generation stability characterization platform that's helping biomanufacturers bring automation into the analytical core of their development and process control
Unfolding insights: How nanoDSF is reshaping biotherapeutics development at Johnson & Johnson Innovative Medicine
Dr. Marius Müller of Johnson & Johnson Innovative Medicine shares insights from questions about the use of nanoDSF™ technology for ID-testing and at several late stages of biotherapeutics development.
53:00Cube x NanoTemper Webinar Series – Episode 2: Optimization of Membrane Proteins for Cryo-EM with Prometheus Panta
Explore a comprehensive, data-driven workflow—rooted in real-world results—combining the NativeMP platform with Prometheus Panta.
NanoTemper Announces Prometheus Panta C: Powering Biopharma Breakthroughs from Preclinical to Commercial Manufacturing
NanoTemper Technologies announces the launch of Prometheus Panta C, a solution designed to meet the evolving needs of biopharmaceutical development—from preclinical phase to commercial manufacturing.
Learn how to enhance your lab's efficiency with Prometheus Panta, from using capillary chips for high-throughput sample loading to solutions for seamless integration in automated workflows
3 trends shaping the future of Biomanufacturing
Expert Marius Müller, PhD, Team Lead at Johnson & Johnson Innovative Medicine, shares insights into three significant trends that have potential to reshape the biopharma and biomanufacturing industry
1:45Increase your throughput, improve precision, and streamline your workflow by automating biologics characterization. Discover Prometheus Panta, an instrument for multi-parameter stability measurements
31:28Watch this webinar to discover how Dr. Marius Müller from Johnson & Johnson Innovative Medicine, uses nanoDSF, a high-throughput method that assesses protein stability, for drug substance ID testing.
5 biologics conferences you won’t want to miss in 2025
Use this curated list of must-attend 2025 biologics conferences to plan your year. Find out when and where each conference takes place, who will be there, and what you can expect.
43:09Learn about technologies and instruments that maintain membrane protein stability and allow structural abd affinity screening studies in their natural lipid environment.
26:58Watch this webinar about approaches and insights into bispecific formulation development and screening with Prometheus Panta for thermal and colloidal stability characterization of biotherapeutics.
How Pierre Fabre Laboratories enhances their antibody developability platform
Learn how Pierre Fabre uses multi-parameter stability measurements of mAb libraries on Prometheus Panta to streamline developability platforms, reducing complexity, cost, and sample consumption.
Optimization of membrane proteins for cryo-EM: Screening of copolymer nanodiscs with Prometheus Panta
Membrane proteins present challenges for structural analysis by cryo-EM; Screening of synthetic copolymers with nanoDSF and DLS on Prometheus Panta help select the best solubilization conditions.
Why Dr. Elsa Wagner from Pierre Fabre chose Prometheus Panta for mAbs developability assessment
Read why scientist Dr. Elsa Wagner chose the Prometheus Panta instrument with simultaneous measurements of DLS, nanoDSF, SLS and backreflection for developability assessment of their mAbs candidates.
4:51Four integrated technologies for biologics developability assessment
The decisions you make about your biologics candidates early in the pipeline ultimately affect their success as therapeutics. Combine sizing and stability information to develop successful biologics
9:42Virtual Prometheus Panta demo: Four integrated technologies for protein stability characterization
Your protein stability characterization projects require tools that provide high-precision, high-quality data to support your selection process. Watch this 10 min walkthrough of Prometheus Panta.
16:24De-risk your antibody characterization workflows with high-quality, multi-parameter stability data from Prometheus Panta
Get developability profiles for monoclonal antibodies with stability data from Prometheus Panta to inform on rational design and selection of therapeutic constructs that will succeed in the clinic.